CLC number: R542.2
On-line Access: 2019-08-05
Received: 2019-01-12
Revision Accepted: 2019-05-04
Crosschecked: 2019-07-09
Cited: 0
Clicked: 3910
Dong-Fei Wang, Jia-Lan Lyu, Juan Fang, Jian Chen, Wan-Wan Chen, Jia-Qi Huang, Shu-Dong Xia, Jian-Mei Jin, Fang-Hong Dong, Hong-Qiang Cheng, Ying-Ke Xu, Xiao-Gang Guo. Impact of LDB3 gene polymorphisms on clinical presentation and implantable cardioverter defibrillator (ICD) implantation in Chinese patients with idiopathic dilated cardiomyopathy[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B1900017 @article{title="Impact of LDB3 gene polymorphisms on clinical presentation and implantable cardioverter defibrillator (ICD) implantation in Chinese patients with idiopathic dilated cardiomyopathy", %0 Journal Article TY - JOUR
中国汉族特发性扩张型心肌病患者LDB3基因多态性与临床表现及植入型心律转复除颤器(ICD)植入的相关性研究创新点:首次明确LDB3基因多态性与中国汉族特发性扩张型心肌病发病密切相关,发现了三个与脑钠肽、舒张压、左室射血分数相关的多态性位点和一个与植入心律转复除颤器相关的多态性位点. 方法:本研究纳入我院159例中国汉族特发性扩张型心肌病患者和247例无亲缘关系健康对照并收集基线临床资料.提取外周血DNA后,聚合酶链式反应扩增LDB3基因的14个外显子,经Sanger一代测序,获得基因突变位点.通过关联分析,研究基因多态性与特发性扩张型心肌病发病之间的相关性.根据连锁不平衡系数和基因分布频率进行单倍体分析,研究不同单倍体分型对特发性扩张型心肌病发病的影响. 结论:在LDB3基因多态性分析中,发现9个多态性位点符合哈代-温伯格平衡.其中rs4468255位点多态性与中国汉族特发性扩张型心肌病发病密切相关.rs11812601、rs56165849和rs3740346位点多态性与患者舒张压、左室射血分数存在显著关联(P<0.05).且携带rs4468255多态性的患者更倾向于安装植入型心律转复除颤器. 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]Bänsch D, Antz M, Boczor S, et al., 2002. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the cardiomyopathy trial (CAT). Circulation, 105(12):1453-1458. [2]Bondue A, Arbustini E, Bianco A, et al., 2018. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial function of the European Society of Cardiology. Cardiovasc Res, 114(10):1287-1303. [3]Faulkner G, Pallavicini A, Formentin E, et al., 1999. ZASP: a new Z-band alternatively spliced PDZ-motif protein. J Cell Biol, 146(2):465-475. [4]Garfinkel AC, Seidman JG, Seidman CE, 2018. Genetic pathogenesis of hypertrophic and dilated cardiomyopathy. Heart Fail Clin, 14(2):139-146. [5]Glöcklhofer CR, Steinfurt J, Franke G, et al., 2018. A novel LMNA nonsense mutation causes two distinct phenotypes of cardiomyopathy with high risk of sudden cardiac death in a large five-generation family. EP Europace, 20(12):2003-2013. [6]Halliday BP, Cleland JGF, Goldberger JJ, et al., 2017. Personalizing risk stratification for sudden death in dilated cardiomyopathy: the past, present, and future. Circulation, 136(2):215-231. [7]Hershberger RE, Hedges DJ, Morales A, 2013. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol, 10(9):531-547. [8]Japp AG, Gulati A, Cook SA, et al., 2016. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol, 67(25):2996-3010. [9]Jiang ZH, Wang HY, Michal JJ, et al., 2016. Genome wide sampling sequencing for SNP genotyping: methods, challenges and future development. Int J Biol Sci, 12(1):100-108. [10]Kadish A, Dyer A, Daubert JP, et al., 2004. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med, 350(21):2151-2158. [11]Køber L, Thune JJ, Nielsen JC, et al., 2016. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med, 375(13):1221-1230. [12]Lang RM, Badano LP, Mor-Avi V, et al., 2015. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging, 16(3):233-270. [13]Levitas A, Konstantino Y, Muhammad E, et al., 2016. D117N in Cypher/ZASP may not be a causative mutation for dilated cardiomyopathy and ventricular arrhythmias. Eur J Hum Genet, 24(5):666-671. [14]Li ZH, Ai T, Samani K, et al., 2010. A ZASP missense mutation, S196L, leads to cytoskeletal and electrical abnormalities in a mouse model of cardiomyopathy. Circ Arrhythm Electrophysiol, 3(6):646-656. [15]Lin CS, Guo XG, Lange S, et al., 2013. Cypher/ZASP is a novel A-kinase anchoring protein. J Biol Chem, 288(41):29403-29413. [16]Losurdo P, Stolfo D, Merlo M, et al., 2016. Early arrhythmic events in idiopathic dilated cardiomyopathy. JACC Clin Electrophysiol, 2(5):535-543. [17]Priori SG, Blomström-Lundqvist C, Mazzanti A, et al., 2015. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of Sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J, 36(41):2793-2867. [18]Reibis R, Salzwedel A, Bonaventura K, et al., 2017. Improvement of left ventricular ejection fraction in revascularized postmyocardial patients: indication for statistical fallacy. BMC Res Notes, 10:244. [19]Sheikh F, Bang ML, Lange S, et al., 2007. “Z”eroing in on the role of Cypher in striated muscle function, signaling, and human disease. Trends Cardiovasc Med, 17(8):258-262. [20]Strickberger SA, Hummel JD, Bartlett TG, et al., 2003. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia—AMIOVIRT. J Am Coll Cardiol, 41(10):1707-1712. [21]Tamburro P, Wilber D, 1992. Sudden death in idiopathic dilated cardiomyopathy. Am Heart J, 124(4):1035-1045. [22]Towbin JA, Bowles NE, 2002. The failing heart. Nature, 415(6868):227-233. [23]van der Zwaag PA, van Rijsingen IAW, de Ruiter R, et al., 2013. Recurrent and founder mutations in the Netherlands— phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J, 21(6):286-293. [24]Vatta M, Mohapatra B, Jimenez S, et al., 2003. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J Am Coll Cardiol, 42(11):2014-2027. [25]Weintraub RG, Semsarian C, Macdonald P, 2017. Dilated cardiomyopathy. Lancet, 390(10092):400-414. [26]Wolff G, Lin YF, Karathanos A, et al., 2017. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. Clin Res Cardiol, 106(7):501-513. [27]Yu HJ, Yuan C, Westenbroek RE, et al., 2018. The AKAP Cypher/Zasp contributes to β-adrenergic/PKA stimulation of cardiac CaV1.2 calcium channels. J Gen Physiol, 150(6):883-889. [28]Zheng M, Cheng HQ, Li XD, et al., 2009. Cardiac-specific ablation of Cypher leads to a severe form of dilated cardiomyopathy with premature death. Hum Mol Genet, 18(4):701-713. [29]Zheng M, Cheng HQ, Banerjee I, et al., 2010. ALP/Enigma PDZ–LIM domain proteins in the heart. J Mol Cell Biol, 2(2):96-102. [30]List of electronic supplementary materials [31]Table S1 Primer sequences of LDB3 gene used in polymerase chain reaction [32]Table S2 Hardy-Weinberg equilibrium (HWE) testing among cases and controls Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2024 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>